Abstract
An Investigator Initiated Prospective, Single Arm Observational Study to Evaluate the Safety and Efficacy of Saroglitazar 4 mg in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non- Alcoholic Steatohepatitis (NASH)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have